Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation January 13, 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking ...

Core Insights - Ekso Bionics has successfully demonstrated a proof-of-concept for integrating AI capabilities into its exoskeleton devices, specifically targeting both medical and industrial applications [1][3] - The new AI voice agent, named "Ekso Voice Agent," is designed for intelligent control of the legacy EksoNR device and operates on NVIDIA Jetson Orin Nano hardware [2][3] - The company has a substantial data repository with approximately 350,000 patient sessions and over 15 million data points, which is increasing by an average of 60,000 patient steps daily, positioning it well to leverage AI in exoskeleton technology [3] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility across various applications [5] - The company focuses on improving health and quality of life through advanced robotics, catering to individuals with paralysis and enhancing capabilities in industrial settings [5] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [5] NVIDIA Connect Program - The company has been accepted into the NVIDIA Connect Program, which aims to accelerate product development and enhance cost efficiency for technology companies [4] - Members of this program receive specialized training, priority engineering support, and access to NVIDIA's advanced development kits and GPU platforms [4]

A video of the Ekso Voice Agent demonstration can be accessed here. About NVIDIA Connect NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA's advanced development kits, GPU platforms, and global ecosystem, helping them deliver next-generation solutions in AI and high-performance computing. AI voic ...

Core Points - Ekso Bionics Holdings, Inc. has updated the effective date of its reverse stock split from May 27, 2025, to June 2, 2025, at a ratio of 1-for-15 [1] - The number of outstanding shares will decrease from approximately 35.5 million to about 2.4 million post-split [2] - The reverse stock split was approved by stockholders to raise the per share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Summary by Sections Reverse Stock Split Details - The reverse stock split will not result in fractional shares; any fractional shares will be rounded up to the next whole share [4] - All issued and outstanding shares will be affected, reducing the number of shares issuable upon the exercise of stock options and increasing respective exercise prices [5] Stockholder Information - Stockholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]

SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Comp ...

Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced ...

Company Performance - Ekso Bionics reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and an improvement from a loss of $0.20 per share a year ago, indicating a negative earnings surprise of -9.09% [1] - The company posted revenues of $3.38 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.95%, and down from $3.76 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Outlook - Ekso Bionics shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -3.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $6.32 million, and for the current fiscal year, it is -$0.25 on revenues of $23.99 million [7] - The estimate revisions trend for Ekso Bionics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsJerome Wong - Chief Financial OfficerScott Davis - Chief Executive OfficerBen Haynor - Managing Director Conference Call Participants Swayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsJerome Wong - Chief Financial OfficerScott Davis - Chief Executive OfficerBen Haynor - Managing Director Conference Call Participants Swayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Stephen Comer of Investor Relations. Thank you. You may begin. Speaker1 Thank you, operator, and good af ...